SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
of Report (Date of Earliest Event Reported): October 3, 2014
Ekso Bionics Holdings, Inc.
Name of Registrant as specified in its charter)
|(State or Other Jurisdiction of
|(Commission File Number)
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices,
including zip code)
(Registrant’s telephone number, including
(Registrant’s name or former address,
if change since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|o||Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|o||Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|o||Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|o||Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of President and Chief Commercial Officer
On October 8, 2014, the Board of Directors of Ekso
Bionics Holdings, Inc. (the “Company”) appointed Thomas Looby to serve as President and Chief Commercial Officer
of the Company, effective immediately. As President and Chief Commercial Officer, Mr. Looby will be responsible for the daily
operations of the Sales, Marketing, Clinical, Customer Service, and Quality departments of the Company. Mr. Looby will report
directly to Nathan Harding, the Company’s Chief Executive Officer.
Mr. Looby, age 42, joined the Company in April 2014,
serving since then as the Company’s Chief Marketing Officer leading the development and execution of the
Company’s global hospital and rehabilitation marketing strategy. Prior to joining the Company, from September 2006 to
March 2014, Mr. Looby served as Senior Vice President and Chief Marketing Officer at Given
Imaging, where he was responsible for worldwide market development for PillCam® capsule endoscopy and other novel
diagnostic technologies to gastrointestinal diseases. Prior to joining Given Imaging, Mr. Looby also served as Corporate
Director of Marketing and Business Development at Eastman Kodak.
Departure of Directors or Certain Officers
Frank Moreman’s employment as Chief Operating Officer
of the Company terminated effective October 3, 2014.
Item 7.01 Regulation FD Disclosure.
On October 9, 2014, the Company issued a press release announcing
the appointment of Mr. Looby as described above. A copy of the press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated by reference herein.
The information in this Item 7.01, including the exhibit attached
hereto, is furnished pursuant to Item 7.01 and shall not be deemed “filed” for any other purpose, including for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that Section. The information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed incorporated
by reference into any filing under the Securities Act of 1933 or the Exchange Act regardless of any general incorporation language
in such filing unless specifically provided otherwise.
Item 9.01 Financial Statements and Exhibits
|99.1||Press Release dated October 9, 2014.
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
||EKSO BIONICS HOLDINGS, INC.
||Chief Executive Officer
Dated: October 9, 2014